\t国药控股(01099.HK)3月20日举行董事会会议审批年度业绩

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) will hold a board meeting on March 20, 2026, to consider and approve the annual performance for the twelve months ending December 31, 2025, and to declare dividends if applicable [1] Group 2 - The meeting is scheduled for a Friday, indicating a strategic timing for financial disclosures [1] - The focus will be on both the company and its subsidiaries, highlighting the importance of consolidated performance [1] - The announcement suggests a forward-looking approach to financial management and shareholder returns [1]